WO2009018909A2 - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors - Google Patents

Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors Download PDF

Info

Publication number
WO2009018909A2
WO2009018909A2 PCT/EP2008/005843 EP2008005843W WO2009018909A2 WO 2009018909 A2 WO2009018909 A2 WO 2009018909A2 EP 2008005843 W EP2008005843 W EP 2008005843W WO 2009018909 A2 WO2009018909 A2 WO 2009018909A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
phenyl
branched
linear
Prior art date
Application number
PCT/EP2008/005843
Other languages
French (fr)
Other versions
WO2009018909A3 (en
Inventor
Maurizio Delcanale
Gabriele Amari
Elisabetta Armani
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2008801023963A priority Critical patent/CN101796028B/en
Priority to DK08784827.1T priority patent/DK2185515T3/en
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Priority to RS20160145A priority patent/RS54606B1/en
Priority to NZ583103A priority patent/NZ583103A/en
Priority to MX2010001544A priority patent/MX2010001544A/en
Priority to BRPI0814065A priority patent/BRPI0814065B8/en
Priority to KR1020107002838A priority patent/KR101200683B1/en
Priority to MEP-2010-19A priority patent/ME00974B/en
Priority to JP2010519351A priority patent/JP2010535722A/en
Priority to EA201000149A priority patent/EA017530B1/en
Priority to PL08784827T priority patent/PL2185515T3/en
Priority to ES08784827.1T priority patent/ES2563478T3/en
Priority to AU2008286027A priority patent/AU2008286027B2/en
Priority to CA2695580A priority patent/CA2695580C/en
Priority to EP08784827.1A priority patent/EP2185515B1/en
Priority to SI200831590T priority patent/SI2185515T1/en
Publication of WO2009018909A2 publication Critical patent/WO2009018909A2/en
Publication of WO2009018909A3 publication Critical patent/WO2009018909A3/en
Priority to TNP2010000044A priority patent/TN2010000044A1/en
Priority to IL203712A priority patent/IL203712A/en
Priority to ZA2010/00832A priority patent/ZA201000832B/en
Priority to HK10112226.9A priority patent/HK1145686A1/xx
Priority to IL239466A priority patent/IL239466A0/en
Priority to HRP20160292TT priority patent/HRP20160292T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Definitions

  • the present invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof. BACKGROUND OF THE INVENTION
  • Airway obstruction characterizes a number of severe respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). Events leading to airway obstruction include oedema of airway walls, increased mucous production and inflammation.
  • COPD chronic obstructive pulmonary disease
  • Drugs for treating respiratory diseases such as asthma and COPD are currently administered through inhalation.
  • One of the advantages of the inhalatory route over the systemic one is the possibility of delivering the drug directly at site of action, avoiding any systemic side-effects, thus resulting in a more rapid clinical response and a higher therapeutic ratio.
  • Inhaled corticosteroids are the current maintenance therapy of choice for asthma and together with bronchodilator beta2-agonists for acute symptom relief, they form the mainstay of current therapy for the disease.
  • the current management of COPD is largely symptomatic by means of bronchodilating therapy with inhaled anticholinergics and inhaled beta2- adrenoceptor agonists.
  • corticosteroids do not reduce the inflammatory response in COPD as they do in asthma.
  • PDEs phosphodiesterases
  • PDE4 inhibitors Various compounds acting as PDE4 inhibitors have been disclosed in the prior art. However, the usefulness of several PDE4 inhibitors of the first - generation such as rolipram and piclamilast has been limited due to their undesirable side effects. Said effects include nausea and emesis due to their action on PDE4 in the central nervous system and gastric acid secretion due to the action on PDE4 in parietal cells in the gut.
  • PDE4 exists in two distinct forms representing different conformations, that were designated as high affinity rolipram binding site or HPDE4, especially present in the central nervous system and in parietal cells, and low affinity rolipram binding site or LPDE4 (Jacobitz, S et al MoI. Pharmacol, 1996, 50, 891-899), which is found in the immune and inflammatory cells. While both forms appear to exhibit catalytic activity, they differ with respect to their sensitivity to inhibitors. In particular compounds with higher affinity for LPDE4 appear less prone to induce side-effects such as nausea, emesis and increased gastric secretion.
  • EP 1634606 discloses, among others, ketone derivatives like benzofuran or 1 ,3-benzodioxole derivatives.
  • WO 9402465 discloses, among others, ketone derivatives of general formula wherein Ri is lower alkyl and R2 may be alkyl, alkenyl, cycloalkyl, cycloalkyl, cycloalkenyl, cyclothioalkyl or cyclothioalkenyl.
  • WO 9535281 in the name of Celltech Therapeutics concerns tri-substituted phenyl derivatives.
  • PDE4 inhibitors have been disclosed so far, there is still a need for more efficacious and better tolerated compounds.
  • it would be highly advantageous to provide more selective compounds e.g. endowed with a higher affinity toward the LPDE4 with respect to the affinity to HPDE4, in order to attenuate or avoid the side effects associated with its inhibition.
  • the present invention addresses these issues by providing PDE4 inhibitors having an improved selectivity toward LPDE4.
  • the invention is directed to compounds acting as inhibitors of the phosphodiesterase 4 (PDE4) enzyme, methods of preparing said compounds, compositions containing them and therapeutic use thereof.
  • PDE4 phosphodiesterase 4
  • Z is selected from the group consisting of
  • R4 is independently selected from H or a linear or branched (C1-C4) alkyl, preferably methyl, optionally substituted by a (C1-C4) cycloalkyl and R5 is independently selected from the group consisting of
  • R' is linear or branched (C1-C4) alkyl, preferably t-butyl.
  • Ri and R 2 are different or the same and are independently selected from the group consisting of
  • R3 is one or more substituents independently selected from the group consisting of H, CN, NO2, CF3 and halogen atoms.
  • A is a ring system, that is a mono- or bicyclic ring which may be saturated, partially unsaturated or unsaturated, such as aryl, (C3-C8) cycloalkyl or heteroaryl, said ring system A having 5 to 10 ring atoms in which at least one ring atom is a heteroatom (e.g. N, S or O), in which the optional substituent R x on the A ring system may be one or more, may be the same or different, and is independently selected from the group consisting of: - linear or branched (Ci-C ⁇ ) alkyl optionally substituted by one or more (C3-C7) cycloalkyl;
  • C1-C10 alkyl optionally substituted by one or more (C3-C7) cycloalkyl; - (C 3 -C 7 ) cycloalkyl;
  • Re and R9 are independently selected from the group consisting of H, linear or branched (Ci-C 6 ) alkyl and they form with the nitrogen atom to which they are linked a saturated, partially saturated or unsaturated ring, preferably NRSR ⁇ is linked to (C1-C10) alkyl forming for example saturated, partially saturated or unsaturated piperidine, oxazine, imidazole rings, wherein these rings are optionally substituted by (C1-C4) alkyl; and
  • R10 and Rn are different or the same and are independently selected from the group consisting of
  • R12 is selected from the group consisting of
  • R12 is phenyl or linear or branched (C1-C6) alkyl
  • R13 is (C1-C4) alkyl or a phenyl optionally substituted with halogen atoms or with a (C1-C4) alkyl group
  • - SO2R14 wherein R14 is (C1-C4) alkyl, OH or NR10R11 wherein R10 and R11 are as defined above;
  • R15 is phenyl or (C1-C4) alkyl
  • R16 is H, phenyl or (C1-C4) alkyl
  • the invention also encompasses the pharmaceutically acceptable salts and/or solvates thereof.
  • the invention further involves the corresponding N-oxides on the pyridine ring.
  • the invention further comprises a process for the preparation of compounds of general formula (I).
  • the present invention also provides pharmaceutical compositions of compounds of general formula (I) alone or in combination with in admixture with one or more pharmaceutically acceptable carriers.
  • the present invention provides the use of the compounds of general formula (I) as a medicament.
  • the present invention provides the use of the compounds of general formula (I) for the manufacture of a medicament.
  • the present invention provides the use of the compounds of general formula (I) for the prevention and/or treatment of any disease characterized by phosphodiesterase 4 (PDE4) overactivity and/or wherein an inhibition of PDE4 activity is desirable.
  • PDE4 phosphodiesterase 4
  • the compounds of general formula (I) alone or combined with other active ingredients may be administered for the prevention and/or treatment of a disease the respiratory tract characterized by airway obstruction such as asthma and COPD.
  • the present invention provides the use of compounds of general formula (I) for the preparation of a medicament for the prevention and/or treatment of an inflammatory disease, disorder or condition characterized by or associated with an undesirable inflammatory immune response or induced by or associated with an excessive secretion of TNF- ⁇ and PDE4.
  • the present invention provides a method for prevention and/or treatment of any disease wherein PDE4 inhibition is required, said method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of general formula (I).
  • halogen atoms as used herein includes fluorine, chlorine, bromine, and iodine, preferably chlorine.
  • linear or branched (Ci-C x ) alkyl where x is an integer greater than 1 , refers to straight-chained and branched alkyl groups wherein the number of constituent carbon atoms is in the range 1 to x.
  • Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl.
  • one or more hydrogen atoms can be replaced by halogen atoms, preferably chlorine or fluorine.
  • (C3-C x ) cycloalkyl refers to cyclic non-aromatic hydrocarbon groups containing from 3 to x ring carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Optionally in said groups one or more hydrogen atoms can be replaced by halogen atoms, preferably chlorine or fluorine.
  • (C3-C7) heterocycloalkyl refers to cyclic non-aromatic hydrocarbon groups containing one or more heteroatoms (e.g. N, S or O), optionally substituted by one or more (C1-C4) alkyl.
  • heteroatoms e.g. N, S or O
  • (C1-C4) alkyl optionally substituted by one or more (C1-C4) alkyl.
  • the derived expressions "(Ci-C x ) cycloalkoxyl” is to be construed in an analogous manner.
  • ring system refers to mono- or bicyclic ring systems which may be saturated, partially unsaturated or unsaturated, such as aryl, (C3-C8) cycloalkyl or heteroaryl, having 5 to 10 ring atoms in which at least one ring atom is a hereoatom (e.g. N, S or O).
  • Suitable monocyclic systems include phenyl, pyridyl, piperazinyl, piperidinyl, morpholinyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, dioxane, imidazole and imidazolidine.
  • bicyclic systems include naphthyl, quinolinyl, isoquinolinyl, indenyl, fluorene, benzimidazole, benzimidazolidine, xanthine and the partially- or fully- hydrogenated derivatives thereof.
  • the invention is directed to a class of compounds acting as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.
  • PDE4 phosphodiesterase 4
  • Said class of compounds inhibits the conversion of cyclic nucleotides, in particular cyclic adenosine monophosphate (cAMP), into their inactive 5'-mononucleotide forms.
  • cyclic nucleotides in particular cyclic adenosine monophosphate (cAMP)
  • cAMP cyclic adenosine monophosphate
  • cyclic nucleotides in particular of cAMP, lead to the suppression of the activity of immune and pro-inflammatory cells such as mast cells, macrophages, T lymphocytes, eosinophils and neutrophils, resulting in a decrease of the release of inflammatory mediators which include cytokines such as IL-1 , IL-3 and tumor necrosis factor -alpha (TNF- ⁇ ).
  • cytokines such as IL-1 , IL-3 and tumor necrosis factor -alpha (TNF- ⁇ ).
  • the catalytic site of PDE4 has been previously identified: it mainly comprises a hydrophobic region in which two sub-pockets are present, e.g. S 0 and Si, and a hydrophilic region containing the metal ions Zn 2+ and Mg 2+ , that in turn comprises the sub-pocket S2 spreading around the metal ions and a sub-pocket S3 which branches approximately 90° from the middle of the hydrophobic pocket.
  • the present invention is directed to compounds which were designed so that they could maintain the interactions with the sub-pockets S 0 and Si by means of the substituted catechol moiety and the interaction with the metal ions region by means of the pyridine ring like other known PDE4 inhibitors but differ for the presence of a further group able of establishing an additional interaction with the sub-pocket S3.
  • the present invention relates to derivatives of 1-phenyl-2- pyridinyl alkyl alcohols of general formula (I)
  • Pharmaceutically acceptable salts include those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid.
  • the compounds according to the invention may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
  • the compounds of general formula (I) were found to show an in vitro inhibitory activity toward the PDE4 enzyme in the nM range and they turned out to be endowed of a good activity in the lungs upon intra-tracheal administration in an animal model of COPD.
  • a preferred group of compounds of general formula (I) is that wherein the 2-pyridinyl ring is substituted in 3 and 5 with two atoms of chlorine, according to the general formula (II)
  • Ri and R2 are both different from H.
  • a first group of more preferred compounds of general formula (II) is that in which: Ri and R2 are as defined above;
  • Z is (CHb) n wherein n is 0;
  • A is as defined above.
  • a second group of more preferred compounds is that in which:
  • Ri and R2 are as defined above;
  • Z is CHR5 wherein R5 is linear or branched (C1-C4) alkyl, preferably methyl;
  • A is as defined above.
  • a third group of more preferred compounds is that in which:
  • Ri and R2 are as defined above;
  • Z is CR4R5 wherein R4 and R5 are both linear or branched (C1-C4) alkyl and they form a ring with the carbon atom to which they are linked having 3, 4, 5 or 6 carbon atoms, preferably having 3 carbon atoms; and
  • A is as defined above.
  • Rx is selected from the group consisting of linear or branched (d-C ⁇ ) alkyl, linear or branched (C2-C6) alkenyl, linear or branched (C2-C6) alkynyl or OR7 wherein R7 is as defined above.
  • R x is a group able of improving the aqueous solubility of the whole molecule such as NR10R11 or HNSO2R13 wherein R10, Rn and R13 are as defined above.
  • the ring is preferably selected from the group consisting of pyrrole, pyrazole, furan, thiophene, imidazole, oxazole, isoxazole, thiazole, pyridine, pyrimidine, pyrazine and pyran, imidazole, imidazolidine and more preferably pyridine.
  • the compounds of the invention are characterized by selectivity toward LPDE4 higher than that toward HPDE4 as obtained by the determination of their IC50.
  • the IC50 is the molar concentration of the test compound producing 50% inhibition of cAMP disappearance, assessed as described in Cortijo J et al Br J Pharmacol 1993, 108: 562-568, while in the case of HPDE4, the IC50 is the molar concentration of the test compound producing 50% inhibition of the binding of [H 3 ] rolipram, assessed as described in Duplantier AJ et al J Med Chem 1996; 39: 120-125.
  • HPDE4/LPDE4 IC50 ratio for the compounds of the invention is higher than 5, preferably higher than 10, more preferably higher than 20 and even more preferably higher than 100.
  • the compounds of general formula (I) may be prepared conventionally according to methods disclosed in the art. Some of the processes which can be used are described below and reported in Scheme and should not be viewed as limiting the scope of the synthetic methods available for the preparation of the compounds of the invention.
  • the compounds of general formula (5) may be prepared according to a process which includes the following steps:
  • 1st step _ Reducing an ethanone derivative of general formula (1) to give an alcohol derivative of general formula (2) (route A).
  • the reaction may be carried out by using sodium boron hydride (NaBH 4 ) in a solvent such as methanol at room temperature under nitrogen atmosphere.
  • NaBH 4 sodium boron hydride
  • reaction is carried out in the presence of a suitable strong base such as lithium diisopropylamide (LDA), NaH, dimethylaminopyridine (DMAP) and in the presence of a condensing agent such as 1-Ethyl-3-[3- dimethylaminopropyl]carbodiimide hydrochloride (EDC) and
  • a suitable strong base such as lithium diisopropylamide (LDA), NaH, dimethylaminopyridine (DMAP)
  • a condensing agent such as 1-Ethyl-3-[3- dimethylaminopropyl]carbodiimide hydrochloride (EDC) and
  • N-hydroxybenzotriazole in a solvent such as dichloromethane under nitrogen atmosphere.
  • solvents such as dimethylformamide (DMF), tetrahydrofuran (THF), chloroform, dioxane and any other aprotic solvent known to those skilled in the art.
  • the reaction may also be carried out in absence of solvents.
  • carboxylic acid A-Z-COOH bears reactive groups like hydroxyl, carboxyl, thio or amino groups, they may need to be protected by protecting groups such as t-butoxycarbonyl, benzyl, benzyloxycarbonyl, methyl, trimethylsilyl and similar and, at a certain step of the synthesis, deprotected to obtain again the free reactive group; the deprotected group may be then reacted with suitable reagents like alkylating, acylating, sulphonylating agents or similar.
  • protecting groups such as t-butoxycarbonyl, benzyl, benzyloxycarbonyl, methyl, trimethylsilyl and similar and, at a certain step of the synthesis, deprotected to obtain again the free reactive group; the deprotected group may be then reacted with suitable reagents like alkylating, acylating, sulphonylating agents or similar.
  • Compounds of general formula (5) may be also prepared by adding a suitable acyl chloride of general formula A-Z-COCI or a suitable isocyanate of general formula A-Z-NCO to a solution of the alcohol derivative of general formula (2), with a suitable base in a stoichiometric or a catalytic amount, according to procedures well known to the skilled person.
  • the alcohol derivative of general formula (2) may alternatively be prepared by reacting a benzaldheyde derivative of formula (3) with a methylpyridine derivative of formula (4) (route B) using lithium-bis-
  • the N-oxides on the 2-pyridinyl ring of the compounds of general formula (5) may be prepared according to methods available in the literature and well known to the skilled person. For instance they may be prepared by dissolving the compound of general formula (5) in CH2CI2 or CHCb, then adding an oxidizing agent such as m-chloro perbenzoic acid (mCPBA) to the resulting solution.
  • mCPBA m-chloro perbenzoic acid
  • Other oxidizing agents which may be used are hydrogen peroxide, perbenzoic acid and peracetic acid.
  • the corresponding N-oxides are alternatively prepared by carrying out the oxidation step before the 2 nd step of the route A.
  • the present invention also provides pharmaceutical compositions of compounds of general formula (I) in admixture with one or more pharmaceutically acceptable carriers, for example those described in Remington's Pharmaceutical Sciences Handbook, XVII Ed., Mack Pub., N. Y.,
  • Administration of the compounds of the present invention may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally and by infusion), by inhalation, rectally, vaginally, topically, locally, transdermal ⁇ , and by ocular administration.
  • Various solid oral dosage forms may be used for administering compounds of the invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders.
  • the compounds of the present invention may be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like.
  • diluents such as sucrose, mannitol, lactose, starches
  • excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like.
  • Time release capsules, tablets and gels are also advantageous in administering the compounds of the present invention.
  • liquid oral dosage forms may also be used for administering compounds of the invention, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs.
  • Such dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention.
  • the compounds of the present invention may be injected, for example, intravenously, in the form of an isotonic sterile solution. Other preparations are also possible.
  • Suppositories for rectal administration of the compounds of the present invention may be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates and polyethylene glycols.
  • a suitable excipient such as cocoa butter, salicylates and polyethylene glycols.
  • Formulations for vaginal administration may be in the form of cream, gel, paste, foam, or spray formula containing, in addition to the active ingredient, such suitable carriers as are known in the art.
  • the pharmaceutical composition may be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear or nose. Topical administration may also involve transdermal administration via means such as transdermal patches.
  • the compounds according to the invention are preferably administered by inhalation. lnhalable preparations include inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations.
  • the powder may be filled in gelatine, plastic or other capsules, cartridges or blister packs or in a reservoir.
  • a diluent or carrier generally non-toxic and chemically inert to the compounds of the invention, e.g. lactose or any other additive suitable for improving the respirable fraction may be added to the powdered compounds of the invention.
  • Inhalation aerosols containing propellant gas such as hydrofluoroalkanes may contain the compounds of the invention either in solution or in dispersed form.
  • the propellant-driven formulations may also contain other ingredients such as co-solvents, stabilizers and optionally other excipients.
  • the propellant-free inhalable formulations comprising the compounds of the invention may be in form of solutions or suspensions in an aqueous, alcoholic or hydroalcoholic medium and they may be delivered by jet or ultrasonic nebulizers known from the prior art or by soft-mist nebulizers such as Respimat ® .
  • the compounds of the invention may be administered as the sole active agent or in combination with other pharmaceutical active ingredients including those currently used in the treatment of respiratory disorders, e.g. beta2-agonists, corticosteroids and anticholinergic or antimuscarinic agents.
  • the dosages of the compounds of the present invention depend upon a variety of factors including the particular disease to be treated, the severity of the symptoms, the route of administration, the frequency of the dosage interval, the particular compound utilized, the efficacy, toxicology profile, and pharmacokinetic profile of the compound.
  • the compounds of general formula (I) may be administered for example, at a dosage comprised between 0.001 and 1000 mg/day, preferably between 0.1 and 500 mg/day.
  • the dosage of the compounds of general formula (I) is advantageously comprised between 0.01 and 20 mg/day, preferably between 0.1 and 10 mg/day.
  • the compounds of general formula (I) alone or combined with other active ingredients may be administered for the prevention and/or treatment of any obstructive respiratory disease such as asthma, chronic bronchitis and chronic obstructive pulmonary disease (COPD).
  • any obstructive respiratory disease such as asthma, chronic bronchitis and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the compounds of general formula (I) may be administered for the prevention and/or treatment of any disease wherein PDE4 inhibition is required.
  • Said disease include: allergic disease states such as atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, toxic and allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritus in the anogenital area, alopecia areata, hypertroph
  • Alzheimer's disease multiple sclerosis, amylolaterosclerosis (ALS), multiple systems atrophy (MSA), schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, depression, stroke, and spinal cord injury.
  • ALS amylolaterosclerosis
  • MSA multiple systems atrophy
  • schizophrenia Parkinson's disease
  • Huntington's disease Huntington's disease
  • Pick's disease depression, stroke, and spinal cord injury.
  • Diisopropylamine 70 mL, 500 mmol was dissolved in dry tetrahydrofuran (THF) (500 mL), the solution was cooled to -10 0 C and butyl lithium (2.5 N in hexane, 210 mL, 525 mmol) was added dropwise under stirring. After 30 minutes the solution was cooled to -20 0 C and 3,5-dichloropyridine (66.6 g, 450 mmol) in tetrahydrofuran (200 mL) was added dropwise.
  • THF dry tetrahydrofuran
  • the crude is purified by flash chromatography on silica gel in gradient elution from petroleum ether/EtOAc 9/1 v/v to petroleum ether/EtOAc 7/3 v/v, to obtain 75 mg of the title compound (50% yield).
  • 3,5-Dichloro-4-methylpyridine 500 mg, 1 eq. is dissolved in dry THF (2 ml_) under nitrogen atmosphere at -60 0 C.
  • LiN(TMS) 2 (1.0M in THF, 3.38 mL, 1.1 eq.) is added dropwise via syringe, keeping the temperature below -55°C.
  • the mixture turns yellow and is stirred at -60 0 C for about 30 minutes.
  • a solution of 3,4-dimethoxybenzaldehyde (513 mg, 1 eq.) in dry THF (2 mL) is added dropwise via syringe, keeping the temperature below -55°C.
  • the crude product is purified by crystallization with ethanol.
  • the white solid is filtered and washed with petroleum ether to yield 70 mg of the title compound.
  • PDE4 activity was determined in cells supernatants by assaying cAMP disappearance from the incubation mixtures. 50 ⁇ l of cell supernatant were incubated at 30 0 C for 30 minutes in a final volume of 200 ⁇ l in the presence of 1.6 ⁇ M cAMP with or without the test compound (50 ⁇ l).
  • the concentration of the test compounds ranged between 10" 12 M and 10" 6 M. Reactions were stopped by heat inactivation (2.5 minutes at 100 0 C) and residual cAMP was measured using an electro-chemiluminescence (ECL) -based immunoassay.
  • ECL electro-chemiluminescence
  • PBMCs peripheral blood mononuclear cells
  • PDE4 inhibitors on the lipopolyshaccarides (LPS)-induced tumour necrosis factor-alpha (TNF- ⁇ release in peripheral blood mononuclear cells (PBMCs) was performed according to a method previously described (Hatzelmann A et al J. Pharmacol. Exp. Ther. 2001 ; 297:267-279; Draheim R et al J. Pharmacol. Exp. Ther. 2004; 308:555-563.
  • Cryopreserved human PBMCs (100 ⁇ l/well) were incubated in 96-well plates (10 5 cells/well), for 30 min, in the presence or absence (50 microl) of the test compounds whose concentrations ranged from 10 12 M to 10 6 M. Subsequently, LPS (3 ng/ml) was added. After 18 h incubation at 37°C in a humidified incubator under an atmosphere of 95% air and 5% CO2, culture medium was collected and TNF- ⁇ measured by ELISA.
  • the concentration of the test compound ranged between 10- 12 M and 10- 5 M.
  • IC50 is the molar concentration of the test compound producing 50% inhibition of cAMP disappearance, while in the case of HPDE4, the IC50 is the molar concentration of the test compound producing 50% inhibition of the binding of [H 3 ] rolipram.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

Description

DERIVATIVES OF 1-PHENYL-2-PYR1DINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS
FIELD OF THE INVENTION
The present invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof. BACKGROUND OF THE INVENTION
Airway obstruction characterizes a number of severe respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). Events leading to airway obstruction include oedema of airway walls, increased mucous production and inflammation.
Drugs for treating respiratory diseases such as asthma and COPD are currently administered through inhalation. One of the advantages of the inhalatory route over the systemic one is the possibility of delivering the drug directly at site of action, avoiding any systemic side-effects, thus resulting in a more rapid clinical response and a higher therapeutic ratio.
Inhaled corticosteroids are the current maintenance therapy of choice for asthma and together with bronchodilator beta2-agonists for acute symptom relief, they form the mainstay of current therapy for the disease. The current management of COPD is largely symptomatic by means of bronchodilating therapy with inhaled anticholinergics and inhaled beta2- adrenoceptor agonists. However, corticosteroids do not reduce the inflammatory response in COPD as they do in asthma.
Another class of therapeutic agents which has been widely investigated in view of its anti-inflammatory effects for the treatment of inflammatory respiratory diseases such as asthma and COPD is represented by the inhibitors of the enzymes phosphodiesterases (PDEs), in particular of the phosphodiesterase type 4 (hereinafter referred to as PDE4).
Various compounds acting as PDE4 inhibitors have been disclosed in the prior art. However, the usefulness of several PDE4 inhibitors of the first - generation such as rolipram and piclamilast has been limited due to their undesirable side effects. Said effects include nausea and emesis due to their action on PDE4 in the central nervous system and gastric acid secretion due to the action on PDE4 in parietal cells in the gut.
The cause of said side effects has been widely investigated. It has been found that PDE4 exists in two distinct forms representing different conformations, that were designated as high affinity rolipram binding site or HPDE4, especially present in the central nervous system and in parietal cells, and low affinity rolipram binding site or LPDE4 (Jacobitz, S et al MoI. Pharmacol, 1996, 50, 891-899), which is found in the immune and inflammatory cells. While both forms appear to exhibit catalytic activity, they differ with respect to their sensitivity to inhibitors. In particular compounds with higher affinity for LPDE4 appear less prone to induce side-effects such as nausea, emesis and increased gastric secretion.
The effort of targeting LPDE4 has resulted in a slight improvement in the selectivity for the second-generation PDE4 inhibitors such as cilomilast and roflumilast. However, even these compounds are not provided with a good selectivity towards LPDE4.
Other classes of compounds acting as PDE4 inhibitors have been disclosed in the prior art. For example, EP 1634606 discloses, among others, ketone derivatives like benzofuran or 1 ,3-benzodioxole derivatives.
WO 9402465 discloses, among others, ketone derivatives of general formula
Figure imgf000004_0001
wherein Ri is lower alkyl and R2 may be alkyl, alkenyl, cycloalkyl, cycloalkyl, cycloalkenyl, cyclothioalkyl or cyclothioalkenyl.
WO 9535281 in the name of Celltech Therapeutics concerns tri-substituted phenyl derivatives.
Both applications are silent about the problems of the side effects associated with inhibition of HPDE4 and do not report data regarding affinity toward HPDE4 and LPDE4.
Therefore, although several PDE4 inhibitors have been disclosed so far, there is still a need for more efficacious and better tolerated compounds. In particular, it would be highly advantageous to provide more selective compounds, e.g. endowed with a higher affinity toward the LPDE4 with respect to the affinity to HPDE4, in order to attenuate or avoid the side effects associated with its inhibition. The present invention addresses these issues by providing PDE4 inhibitors having an improved selectivity toward LPDE4.
As a matter of fact, it has now been found that providing a PDE4 inhibitor with an additional moiety interacting with the active site of the PDE4, there is an improvement in the selectivity of the inhibitors towards LPDE4. The PDE4 inhibitors of the present invention efficaciously act upon inhalation administration and could be characterized by a good persistency in the lung and a short systemic duration. SUMMARY OF THE INVENTION
The invention is directed to compounds acting as inhibitors of the phosphodiesterase 4 (PDE4) enzyme, methods of preparing said compounds, compositions containing them and therapeutic use thereof.
In particular the invention is directed to derivatives of 1-phenyl-2- pyridinyl alkyl alcohols of general formula (I)
Figure imgf000005_0001
(I) wherein:
Z is selected from the group consisting of
(CH2)m wherein m = 0, 1 or 2; (CH2)nO wherein n=1 , 2 or 3;
O(CH2)p wherein p=0, 1 , 2 or 3;
CH2SO2;
CHNR6;
CH2NR6; NR6 wherein R6 is H or a linear or branched (C1-C4) alkyl;
OCOR4R5; and
CR4R5 wherein
R4 is independently selected from H or a linear or branched (C1-C4) alkyl, preferably methyl, optionally substituted by a (C1-C4) cycloalkyl and R5 is independently selected from the group consisting of
- linear or branched (C1-C4) alkyl, preferably methyl;
- phenyl;
- benzyl;
- NH2; and - HNCOOR', wherein R' is linear or branched (C1-C4) alkyl, preferably t-butyl.
Ri and R2 are different or the same and are independently selected from the group consisting of
- H; - linear or branched (C-i-Cβ) alkyl, optionally substituted by one or more substituents selected from (C3-C7) cycloalkyl or (C5-C7) cycloalkenyl;
- (C3-C7) cycloalkyl;
- (C5-C7) cycloalkenyl; - linear or branched (C2-C6) alkenyl; and
- linear or branched (C2-C6) alkynyl.
R3 is one or more substituents independently selected from the group consisting of H, CN, NO2, CF3 and halogen atoms.
A is a ring system, that is a mono- or bicyclic ring which may be saturated, partially unsaturated or unsaturated, such as aryl, (C3-C8) cycloalkyl or heteroaryl, said ring system A having 5 to 10 ring atoms in which at least one ring atom is a heteroatom (e.g. N, S or O), in which the optional substituent Rx on the A ring system may be one or more, may be the same or different, and is independently selected from the group consisting of: - linear or branched (Ci-Cβ) alkyl optionally substituted by one or more (C3-C7) cycloalkyl;
- linear or branched (C2-C6) alkenyl optionally substituted by one or more (C3-C7) cycloalkyl;
- linear or branched (C∑-Cβ) alkynyl optionally substituted by one or more (C3-C7) cycloalkyl;
- (C5-C7) cycloalkenyl;
- phenyl;
- (C3-C7) heterocycloalkyl; - OR7 wherein R7 is selected from the group consisting of
- H;
- (C1-C10) alkyl optionally substituted by one or more (C3-C7) cycloalkyl; - (C3-C7) cycloalkyl;
- (C1-C4) alkyl-(C3-C7) heterocycloalkyl;
- CO (Ci-C6) alkyl;
- COO (Ci-C6) alkyl;
- phenyl; - benzyl;
- (C1-C10) alkyl-NRβRθ wherein Re and R9 are independently selected from the group consisting of H, linear or branched (Ci-C6) alkyl and they form with the nitrogen atom to which they are linked a saturated, partially saturated or unsaturated ring, preferably NRSRΘ is linked to (C1-C10) alkyl forming for example saturated, partially saturated or unsaturated piperidine, oxazine, imidazole rings, wherein these rings are optionally substituted by (C1-C4) alkyl; and
- halogen atoms; - CN;
- NO2;
- NR10R11 wherein R10 and Rn are different or the same and are independently selected from the group consisting of
- H; - linear or branched (Ci-C6) alkyl, optionally substituted with phenyl or (C3-C7) cycloalkyl;
- COC6H5;
- CO-(Ci-C4) alkyl; - COO-(Ci-C4) alkyl;
- CONH-(Ci-C6) alkyl-Ri2, wherein R12 is selected from the group consisting of
- H; - (C1-C4) alkyl;
Figure imgf000008_0001
- CONH (C1-C4) alkyl-N(Ci-C4) alkyl; or they form with the nitrogen atom to which they are linked a saturated or partially saturated ring, preferably a piperidyl ring; - (C1-C4) alkyl-NRioRn;
- COR12 wherein R12 is phenyl or linear or branched (C1-C6) alkyl;
- oxo;
- HNSO2R13 wherein R13 is (C1-C4) alkyl or a phenyl optionally substituted with halogen atoms or with a (C1-C4) alkyl group; - SO2R14 wherein R14 is (C1-C4) alkyl, OH or NR10R11 wherein R10 and R11 are as defined above;
- SOR15 wherein R15 is phenyl or (C1-C4) alkyl;
- SR16 wherein R16 is H, phenyl or (C1-C4) alkyl;
- COOR17 wherein R17 is H, (C1-C4) alkyl, phenyl or benzyl; and - (CH2)qORi8, wherein q=1 , 2, 3 or 4 and Ri8 is H or (C1-C4) cycloalkyl. and pharmaceutically acceptable salts and N-oxides on the pyridine ring thereof.
The invention also encompasses the pharmaceutically acceptable salts and/or solvates thereof.
The invention further involves the corresponding N-oxides on the pyridine ring.
The invention further comprises a process for the preparation of compounds of general formula (I).
The present invention also provides pharmaceutical compositions of compounds of general formula (I) alone or in combination with in admixture with one or more pharmaceutically acceptable carriers. In a further aspect the present invention provides the use of the compounds of general formula (I) as a medicament.
In a further aspect the present invention provides the use of the compounds of general formula (I) for the manufacture of a medicament.
In particular the present invention provides the use of the compounds of general formula (I) for the prevention and/or treatment of any disease characterized by phosphodiesterase 4 (PDE4) overactivity and/or wherein an inhibition of PDE4 activity is desirable.
In particular the compounds of general formula (I) alone or combined with other active ingredients may be administered for the prevention and/or treatment of a disease the respiratory tract characterized by airway obstruction such as asthma and COPD.
In a further aspect the present invention provides the use of compounds of general formula (I) for the preparation of a medicament for the prevention and/or treatment of an inflammatory disease, disorder or condition characterized by or associated with an undesirable inflammatory immune response or induced by or associated with an excessive secretion of TNF-α and PDE4.
Moreover the present invention provides a method for prevention and/or treatment of any disease wherein PDE4 inhibition is required, said method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of general formula (I).
DEFINITIONS
The term "halogen atoms" as used herein includes fluorine, chlorine, bromine, and iodine, preferably chlorine.
As used herein, the expression "linear or branched (Ci-Cx) alkyl" where x is an integer greater than 1 , refers to straight-chained and branched alkyl groups wherein the number of constituent carbon atoms is in the range 1 to x. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl.
Optionally in said groups one or more hydrogen atoms can be replaced by halogen atoms, preferably chlorine or fluorine.
The derived expressions "(C2-C6) alkenyl" and "(C2-C6) alkynyl", are to be construed in an analogous manner.
As used herein, the expression "(C3-Cx) cycloalkyl", where x is an integer greater than 3, refers to cyclic non-aromatic hydrocarbon groups containing from 3 to x ring carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Optionally in said groups one or more hydrogen atoms can be replaced by halogen atoms, preferably chlorine or fluorine.
As used herein, the expression "(C3-C7) heterocycloalkyl", refers to cyclic non-aromatic hydrocarbon groups containing one or more heteroatoms (e.g. N, S or O), optionally substituted by one or more (C1-C4) alkyl. The derived expressions "(Ci-Cx) cycloalkoxyl" is to be construed in an analogous manner.
The derived expression "(Cs-Cx) cycloalkenyl", where x is an integer greater than 5, is to be construed in an analogous manner.
As used herein, the expression "ring system" refers to mono- or bicyclic ring systems which may be saturated, partially unsaturated or unsaturated, such as aryl, (C3-C8) cycloalkyl or heteroaryl, having 5 to 10 ring atoms in which at least one ring atom is a hereoatom (e.g. N, S or O).
Examples of suitable monocyclic systems include phenyl, pyridyl, piperazinyl, piperidinyl, morpholinyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, dioxane, imidazole and imidazolidine.
Examples of suitable bicyclic systems include naphthyl, quinolinyl, isoquinolinyl, indenyl, fluorene, benzimidazole, benzimidazolidine, xanthine and the partially- or fully- hydrogenated derivatives thereof.
DETAILED DESCRIPTION OF THE INVENTION
The invention is directed to a class of compounds acting as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.
Said class of compounds inhibits the conversion of cyclic nucleotides, in particular cyclic adenosine monophosphate (cAMP), into their inactive 5'-mononucleotide forms.
In the airways, the physiological responses to elevated intracellular levels of cyclic nucleotides, in particular of cAMP, lead to the suppression of the activity of immune and pro-inflammatory cells such as mast cells, macrophages, T lymphocytes, eosinophils and neutrophils, resulting in a decrease of the release of inflammatory mediators which include cytokines such as IL-1 , IL-3 and tumor necrosis factor -alpha (TNF-α).
It also leads to an airway smooth muscle relaxation and a decrease in oedema. The catalytic site of PDE4 has been previously identified: it mainly comprises a hydrophobic region in which two sub-pockets are present, e.g. S0 and Si, and a hydrophilic region containing the metal ions Zn2+ and Mg2+, that in turn comprises the sub-pocket S2 spreading around the metal ions and a sub-pocket S3 which branches approximately 90° from the middle of the hydrophobic pocket.
Most of the compounds of the prior art are provided with a moiety able of interacting with the sub-pockets So and Si of the hydrophobic region such as a substituted catechol group and with another moiety able of indirectly interacting with the metal ions of the S2 sub-pocket, for example a heterocycle such as pyridine or pyrrolidone.
The present invention is directed to compounds which were designed so that they could maintain the interactions with the sub-pockets S0 and Si by means of the substituted catechol moiety and the interaction with the metal ions region by means of the pyridine ring like other known PDE4 inhibitors but differ for the presence of a further group able of establishing an additional interaction with the sub-pocket S3.
In particular the present invention relates to derivatives of 1-phenyl-2- pyridinyl alkyl alcohols of general formula (I)
Figure imgf000012_0001
(I)
Pharmaceutically acceptable salts include those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid.
It will be apparent to those skilled in the art that the compounds of general formula (I) may contain asymmetric centers. Therefore the invention also includes the optical stereoisomers and mixtures thereof.
Where the compounds according to the invention have at least one asymmetric center, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
The compounds of general formula (I) were found to show an in vitro inhibitory activity toward the PDE4 enzyme in the nM range and they turned out to be endowed of a good activity in the lungs upon intra-tracheal administration in an animal model of COPD.
They also exhibited in some cases sustained pulmonary levels in the lungs, while no detectable plasmatic levels were found which is an index of a short systemic action. One possible explanation for the unexpectedly high selectivity of these compounds for LPDE4 in comparison to HPDE4 is that they all feature a moiety which could fit into the S3 sub-pocket of the catalytic site of the PDE4 enzyme through the A substituent.
As it can be appreciated from the results reported in the Example 13, a compound representative of the invention was indeed found about 1319-fold more selective toward LPDE4 versus HPDE4.
A preferred group of compounds of general formula (I) is that wherein the 2-pyridinyl ring is substituted in 3 and 5 with two atoms of chlorine, according to the general formula (II)
Figure imgf000013_0001
(II) wherein Ri, R2, Z and A are as defined above. Advantageously when Ri or R2 is H, the other substituent on the catechol group is different from H.
Preferably Ri and R2 are both different from H.
A first group of more preferred compounds of general formula (II) is that in which: Ri and R2 are as defined above;
Z is (CHb)n wherein n is 0; and
A is as defined above.
A second group of more preferred compounds is that in which:
Ri and R2 are as defined above; Z is CHR5 wherein R5 is linear or branched (C1-C4) alkyl, preferably methyl; and
A is as defined above.
A third group of more preferred compounds is that in which:
Ri and R2 are as defined above; Z is CR4R5 wherein R4 and R5 are both linear or branched (C1-C4) alkyl and they form a ring with the carbon atom to which they are linked having 3, 4, 5 or 6 carbon atoms, preferably having 3 carbon atoms; and
A is as defined above.
In one of the preferred embodiment A is substituted and Rx is selected from the group consisting of linear or branched (d-Cβ) alkyl, linear or branched (C2-C6) alkenyl, linear or branched (C2-C6) alkynyl or OR7 wherein R7 is as defined above.
In another preferred embodiment A is substituted and Rx is a group able of improving the aqueous solubility of the whole molecule such as NR10R11 or HNSO2R13 wherein R10, Rn and R13 are as defined above.
In a particular embodiment of the invention, when A is a heteroaryl ring, the ring is preferably selected from the group consisting of pyrrole, pyrazole, furan, thiophene, imidazole, oxazole, isoxazole, thiazole, pyridine, pyrimidine, pyrazine and pyran, imidazole, imidazolidine and more preferably pyridine.
According to a preferred embodiment the present invention provides the compounds reported below:
Figure imgf000015_0001
(continued)
Figure imgf000016_0001
(continued)
Figure imgf000017_0001
(continued)
Figure imgf000018_0001
(continued)
Figure imgf000019_0001
(continued)
Figure imgf000020_0001
(continued)
Figure imgf000021_0001
(continued)
Figure imgf000022_0001
(continued)
Figure imgf000023_0001
Advantageously the compounds of the invention are characterized by selectivity toward LPDE4 higher than that toward HPDE4 as obtained by the determination of their IC50.
In the case of LPDE4, the IC50 is the molar concentration of the test compound producing 50% inhibition of cAMP disappearance, assessed as described in Cortijo J et al Br J Pharmacol 1993, 108: 562-568, while in the case of HPDE4, the IC50 is the molar concentration of the test compound producing 50% inhibition of the binding of [H3] rolipram, assessed as described in Duplantier AJ et al J Med Chem 1996; 39: 120-125.
Preferably the HPDE4/LPDE4 IC50 ratio for the compounds of the invention is higher than 5, preferably higher than 10, more preferably higher than 20 and even more preferably higher than 100.
The compounds of general formula (I) may be prepared conventionally according to methods disclosed in the art. Some of the processes which can be used are described below and reported in Scheme and should not be viewed as limiting the scope of the synthetic methods available for the preparation of the compounds of the invention.
Scheme
X? R3
Figure imgf000024_0001
(1) (2) (3) W
a base + a condensing agent a base a base
Figure imgf000024_0002
Figure imgf000024_0003
(5)
For instance, according to a particular embodiment of the present invention (scheme), the compounds of general formula (5) may be prepared according to a process which includes the following steps:
1st step _ Reducing an ethanone derivative of general formula (1) to give an alcohol derivative of general formula (2) (route A). The reaction may be carried out by using sodium boron hydride (NaBH4) in a solvent such as methanol at room temperature under nitrogen atmosphere.
2nd step - Adding a suitable acid of formula AZCOOH to a solution of the alcohol derivative of general formula (2) to give a compound of general formula (5).
The reaction is carried out in the presence of a suitable strong base such as lithium diisopropylamide (LDA), NaH, dimethylaminopyridine (DMAP) and in the presence of a condensing agent such as 1-Ethyl-3-[3- dimethylaminopropyl]carbodiimide hydrochloride (EDC) and
N-hydroxybenzotriazole (HOBT) in a solvent such as dichloromethane under nitrogen atmosphere. Other solvents may be used, such as dimethylformamide (DMF), tetrahydrofuran (THF), chloroform, dioxane and any other aprotic solvent known to those skilled in the art. In a particular embodiment, the reaction may also be carried out in absence of solvents.
In case the carboxylic acid A-Z-COOH bears reactive groups like hydroxyl, carboxyl, thio or amino groups, they may need to be protected by protecting groups such as t-butoxycarbonyl, benzyl, benzyloxycarbonyl, methyl, trimethylsilyl and similar and, at a certain step of the synthesis, deprotected to obtain again the free reactive group; the deprotected group may be then reacted with suitable reagents like alkylating, acylating, sulphonylating agents or similar.
The protection and deprotection of functional groups is described in "Protective Groups in Organic Chemistry" 3rd edition, T.W. Greene and P. G. M. Wuts, Wiley-lnterscience (1999) and "Protecting Groups", P.J. Kocienski, Georg Thieme Verlag (1994).
Compounds of general formula (5) may be also prepared by adding a suitable acyl chloride of general formula A-Z-COCI or a suitable isocyanate of general formula A-Z-NCO to a solution of the alcohol derivative of general formula (2), with a suitable base in a stoichiometric or a catalytic amount, according to procedures well known to the skilled person.
The alcohol derivative of general formula (2) may alternatively be prepared by reacting a benzaldheyde derivative of formula (3) with a methylpyridine derivative of formula (4) (route B) using lithium-bis-
(trimethylsilyl)-amide (LiHMDS) or similar strong bases and a solvent such as tetrahydrofuran (THF) or other aprotic solvents.
Intermediates of general formula (3) and (4) are commercially available or may be prepared according to methods available in the literature and well known to the person skilled in the art.
The N-oxides on the 2-pyridinyl ring of the compounds of general formula (5) may be prepared according to methods available in the literature and well known to the skilled person. For instance they may be prepared by dissolving the compound of general formula (5) in CH2CI2 or CHCb, then adding an oxidizing agent such as m-chloro perbenzoic acid (mCPBA) to the resulting solution. Other oxidizing agents which may be used are hydrogen peroxide, perbenzoic acid and peracetic acid.
For those compounds in which A is a ring substituted with a functional group sensitive to oxidation, the corresponding N-oxides are alternatively prepared by carrying out the oxidation step before the 2nd step of the route A.
The present invention also provides pharmaceutical compositions of compounds of general formula (I) in admixture with one or more pharmaceutically acceptable carriers, for example those described in Remington's Pharmaceutical Sciences Handbook, XVII Ed., Mack Pub., N. Y.,
U.S.A.
Administration of the compounds of the present invention may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally and by infusion), by inhalation, rectally, vaginally, topically, locally, transdermal^, and by ocular administration. Various solid oral dosage forms may be used for administering compounds of the invention including such solid forms as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders. The compounds of the present invention may be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like. Time release capsules, tablets and gels are also advantageous in administering the compounds of the present invention.
Various liquid oral dosage forms may also be used for administering compounds of the invention, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs. Such dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention. The compounds of the present invention may be injected, for example, intravenously, in the form of an isotonic sterile solution. Other preparations are also possible.
Suppositories for rectal administration of the compounds of the present invention may be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates and polyethylene glycols. Formulations for vaginal administration may be in the form of cream, gel, paste, foam, or spray formula containing, in addition to the active ingredient, such suitable carriers as are known in the art.
For topical administration the pharmaceutical composition may be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear or nose. Topical administration may also involve transdermal administration via means such as transdermal patches. For the treatment of the diseases of the respiratory tract, the compounds according to the invention are preferably administered by inhalation. lnhalable preparations include inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations.
For administration as a dry powder, single- or multi-dose inhalers known from the prior art may be utilized. In that case the powder may be filled in gelatine, plastic or other capsules, cartridges or blister packs or in a reservoir. A diluent or carrier, generally non-toxic and chemically inert to the compounds of the invention, e.g. lactose or any other additive suitable for improving the respirable fraction may be added to the powdered compounds of the invention.
Inhalation aerosols containing propellant gas such as hydrofluoroalkanes may contain the compounds of the invention either in solution or in dispersed form. The propellant-driven formulations may also contain other ingredients such as co-solvents, stabilizers and optionally other excipients.
The propellant-free inhalable formulations comprising the compounds of the invention may be in form of solutions or suspensions in an aqueous, alcoholic or hydroalcoholic medium and they may be delivered by jet or ultrasonic nebulizers known from the prior art or by soft-mist nebulizers such as Respimat®. The compounds of the invention may be administered as the sole active agent or in combination with other pharmaceutical active ingredients including those currently used in the treatment of respiratory disorders, e.g. beta2-agonists, corticosteroids and anticholinergic or antimuscarinic agents. The dosages of the compounds of the present invention depend upon a variety of factors including the particular disease to be treated, the severity of the symptoms, the route of administration, the frequency of the dosage interval, the particular compound utilized, the efficacy, toxicology profile, and pharmacokinetic profile of the compound. Advantageously, the compounds of general formula (I) may be administered for example, at a dosage comprised between 0.001 and 1000 mg/day, preferably between 0.1 and 500 mg/day.
When they are administered by inhalation route, the dosage of the compounds of general formula (I) is advantageously comprised between 0.01 and 20 mg/day, preferably between 0.1 and 10 mg/day.
Preferably, the compounds of general formula (I) alone or combined with other active ingredients may be administered for the prevention and/or treatment of any obstructive respiratory disease such as asthma, chronic bronchitis and chronic obstructive pulmonary disease (COPD). However the compounds of general formula (I) may be administered for the prevention and/or treatment of any disease wherein PDE4 inhibition is required. Said disease include: allergic disease states such as atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, toxic and allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritus in the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, systemic lupus erythematosus, follicular and wide-area pyodermias, endogenous and exogenous acne, acne rosacea, Beghet's disease, anaphylactoid purpura nephritis, inflammatory bowel disease, leukemia, multiple sclerosis, gastrointestinal diseases, autoimmune diseases and the like.
They also include neurological and psychiatric disorders such as Alzheimer's disease, multiple sclerosis, amylolaterosclerosis (ALS), multiple systems atrophy (MSA), schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, depression, stroke, and spinal cord injury.
The present invention will now be further described by way of the following non-limiting examples.
I=XAMPLES EXAMPLE 1
Preparation of 3,5-dichloro-4-methylpyridine (Intermediate (4) of scheme)
Diisopropylamine (70 mL, 500 mmol) was dissolved in dry tetrahydrofuran (THF) (500 mL), the solution was cooled to -100C and butyl lithium (2.5 N in hexane, 210 mL, 525 mmol) was added dropwise under stirring. After 30 minutes the solution was cooled to -200C and 3,5-dichloropyridine (66.6 g, 450 mmol) in tetrahydrofuran (200 mL) was added dropwise. The solution was stirred at -100C for 30 minutes, cooled to -70°C and added dropwise with iodomethane (50 mL, 1.6 mol) in tetrahydrofuran (100 mL). The reaction mixture was allowed to warm to room temperature, quenched with water (100 mL) and extracted with diethyl ether (3 x 100 mL); the combined organic layers were dried over sodium sulphate (5 g) and evaporated to dryness. The crude product was crystallized twice from aqueous ethanol than from hexane to afford 3,5-dichloro-4- methylpyridine (49.9 g, 306 mmol, 68 % yield) as a white solid.
MS/ESI+ 162-164-166 m/z [MH] +.
EXAMPLE 2 Preparation of 2-(3>5-dichloro-pyridin-4-yl)-1-(3,4-dimethoxy-phenyl)- ethanone (Intermediate (1) of scheme)
A solution of 3,5-dichloro-4-methyl-pyridine (2.06 g, 12.7 mmol) in dry tetrahydrofuran (30 ml) was cooled down to -78°C then a 1.8 M solution of lithium diisopropylamide in tetrahydrofuran (7.4 ml, 13.3 mmol) was added dropwise under stirring, keeping the temperature below -700C. The resulting solution was stirred for 30 min., then a solution of 3,4-dimethoxy-benzoyl chloride (2.55 g, 12.7 mmol) in dry tetrahydrofuran (20 ml) was added dropwise, maintaining the temperature below -700C. After stirring for 15 min. ice (20 g) was added, followed by further 500 ml of water. The mixture was extracted with ethyl acetate (2 x 50 ml), the combined organic layers were dried over sodium sulphate and evaporated under reduced pressure to give an oil that was purified by flash chromatography (Eluent: ethyl acetate/petroleum ether from 10/90 to 30/70 v:v).
2.1 grams (6.4 mmol, 52% yield) of the title compound were obtained as a white solid.
MS/ESI+ 326-328-330 m/z [MH] +; 1H NMR (CDCI3 calibrated at 7.26 ppm) 3.91 and 3.95 (2s, 6H), 4.62 (s, 2H), 6.91-6.95 (d, 1 H), 7.53-7.54 (d, 1 H), 7.67-7.75 (dd, 1H), 8.49 (s, 2H).
The following intermediates were prepared using said route with suitable solvents: Table 1
Figure imgf000032_0001
EXAMPLE 3
Preparation of 2-(3,5-dichloro-pyridin-4-yl)-1-(3,4-dimethoxy-phenyl)- ethanol (Intermediate (2) of scheme) Route A
Sodium boron hydride NaBH4 (45.2 mg, 2.5 eq.) is added to a suspension of 2-(3,5-dichloro-pyridin-4-yl)-1 -(3,4-dimethoxy-phenyl)- ethanone (150 mg, 1 eq.) in CH3OH (5 ml), at room temperature under nitrogen atmosphere. The mixture is stirred at room temperature overnight, then the reaction is quenched with water and extracted with EtOAc. The organic layer is dried over Na2SO4 and the solvent is evaporated. The crude is purified by flash chromatography on silica gel in gradient elution from petroleum ether/EtOAc 9/1 v/v to petroleum ether/EtOAc 7/3 v/v, to obtain 75 mg of the title compound (50% yield).
MS/ESI+ 328-330-332[MH] +
The following intermediates were prepared using said route with suitable solvents: Table 2
Figure imgf000033_0001
EXAMPLE 4
Preparation of 2-(3,5-dichloro-pyridin-4-yl)-1 -(3,4-dimethoxy-phenyl)- ethanol (Intermediate (2) of scheme) Route B
3,5-Dichloro-4-methylpyridine (500 mg, 1 eq.) is dissolved in dry THF (2 ml_) under nitrogen atmosphere at -600C. LiN(TMS)2 (1.0M in THF, 3.38 mL, 1.1 eq.) is added dropwise via syringe, keeping the temperature below -55°C. The mixture turns yellow and is stirred at -600C for about 30 minutes. Then a solution of 3,4-dimethoxybenzaldehyde (513 mg, 1 eq.) in dry THF (2 mL) is added dropwise via syringe, keeping the temperature below -55°C. After the addition the mixture is slowly warmed to room temperature and stirred at room temperature for about 2h. Then it is quenched with water and extracted with EtOAc. The organic layer is dried over Na2SO4 and the solvent is evaporated. The crude is triturated with Et2O, and filtered to obtain 741 mg of the title compound as a white solid (73% yield). MS/ESI+ 328-330-332 [MH] + EXAMPLE 5
Preparation of (S)-2-(4-isobutyl-phenyl)-propionic acid 2-(3,5-dichloro- pyridin-4-yl)-1-(3,4-dimethoxy-phenyl)ethyl ester (compound 1)
(1 -Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride) (EDCHCI) (345 mg, 3 eq.) is added to a solution of 2-(3,5-dichloro-pyridin-4- yl)-1-(3,4-dimethoxy-phenyl)-ethanol (200 mg, 1 eq.), (S)-2-(4-isobutyl- phenyl)-propionic acid (148 mg, 1.2 eq.) and 4-dimethylaminopyridine (DMAP) (37 mg, 0.5 eq.) in dry CH2CI2 (8 ml_) at room temperature under nitrogen atmosphere. The mixture is stirred at room temperature overnight, then it is treated with a saturated solution of NH4CI (20 ml) and extracted with EtOAc (2x20 ml). The combined organic layer are dried over Na2SO4 and the solvent is evaporated. The crude is purified by flash chromatography on silica gel in gradient elution (from petroleum ether/EtOAc 9/1 v/v to petroleum ether/EtOAc 7/3 v/v) to yield 259 mg of pure compound. The following compounds were prepared using said route with suitable reagents:
Table 3
Figure imgf000034_0001
(continued) Me Me MS/ESI+ 446-448-450 [MH] +•
1H NMR (CDCb calibrated at
7.26 ppm) δ: 8.42(s*. 2H);
7.26(m*, 3H); 7.17(m*, 2H);
6.89(dd*, 1H); 6.82(d*. 1H);
6.79(d*, 1H); 6.14(dd*. 1H);
3.89(s*, 3H); 3.80(s*, 3H);
3.61 (dd*, 1H) ; 3.58 and
3.55(ABq , 2H); 3.29(dd*. 1H).
Me Me MS/ESI+ 472-474-476 [MH] +•
Η NMR (CDCb calibrated at
Figure imgf000035_0001
7.26 ppm) δ: 8.45(s*, 2H); 7.34-
7.26(m*, 5H); 6.79(m*, 2H);
6.68(m*. 1H); 6.15(dd*, 1H);
3.89(s*, 3H); 3.80(s*, 3H);
3.49(dd*. 1H); 3.15(dd*, 1H);
1.54(m*. 1H); 1.43(m*, 1H);
1.22(m*, 1H); 1.1 0(m*, 1H).
Me Me o— MS/ESI+ 492-494-496 [MH]
1H NMR (CDCb calibrated at
7.26 ppm) δ: 8.47(s*. 1H);
7.72(dd*, 1H); 7.54(d*, 1H);
7.04(dd*, 1H); 7.01 (d*, 1H);
6.89(d*. 1H); 6.88(d*, 1H);
6.34(dd*, 1H); 3.95(s*, 3H);
3.93(s*. 3H); 3.91(s*. 3H);
3.89(s*. 3H); 3.82(dd*. 1H);
3.41 (dd*, 1 H).
CHF2 cyclopropyl- HN'b0C MS/ESI+ 637-639-641 [MH] + • methyl 1H NMR (CDCb calibrated at
7.26 ppm) δ: 8.21 (s*. 2H), ' r.36-
7.22(m*. 3H), 7.16(m*, 3H),
7.00(m*. 2H), 6.65(dd*. 1H),
6.09(dd*, 1H), 5 31 (br* s*, 2H),
3.93(d*, 2H), 3 .54 (dd*, 1 H),
3.17(dd*. 1H), 1.40(s*. 9H),
1.30(m*, 1 H); 0.68(m*, 2H),
0.42(m*. : 2H).
(continued)
Figure imgf000036_0001
(continued)
Figure imgf000037_0001
(EXAMPLE 6
Preparation of (S)-2-(4-isobutyl-phenyl)-propionic acid 2-(3,5-dichloro- 1-oxy-pyridin-4-yl)-1-(3,4-dimethoxy-phenyl)ethyl ester (compound 13)
Compound 1 (51.5 mg, 0.1 mmoles) is dissolved in CH2CL2 (1 ml_). m-Chloro perbenzoic acid (mCPBA, 15 mg, 0.12 mmoles) is added and the resulting solution is stirred at room temperature for 2 hours. The mixture is then diluted with CH2CI2 (5 ml_) and extracted with 1N NaOH (5 ml). The organic phase is dried over Na2SO4 and the solvent is evaporated. The crude is purified by preparative HPLC to yield 37 mg of the title compound. The following compounds were prepared following the same route using suitable reagents: Table 4
Figure imgf000038_0001
(continued)
Figure imgf000039_0001
The following compounds were prepared in an analogous manner to the methods already described in earlier Examples, with appropriate selection of reagents and according to the general synthesis earlier described:
Figure imgf000039_0002
(continued)
Figure imgf000040_0001
(continued)
Figure imgf000041_0001
(continued)
Figure imgf000042_0001
(continued)
Figure imgf000043_0001
(continued)
Figure imgf000044_0001
(continued)
Figure imgf000045_0001
(continued)
Figure imgf000046_0001
EXAMPLE 7
Preparation of 2-(4-amino-phenyl)-propionic acid 2-(3,5-dichloro- pyridin-4-yl)-1-(3,4-dimethoxy-phenyl)ethyl ester (compound 16)
Compound 10 (50 mg, 0.1 mmoles) is dissolved in dimethylformamide (DMF) (3 mL). Tin chloride (SnCb x 2HbO, 113 mg, 0.5 mmoles) is added and the resulting mixture is stirred at room temperature for 17 hours. The mixture is then diluted with water (15 mL) and extracted with Et2θ (2 x 30 mL). The organic phase is dried over Na2SO4 and the solvent is evaporated. The crude is purified by preparative HPLC to yield 10 mg of the title compound. Table 5
Figure imgf000047_0001
EXAMPLE 8
Preparation of 2-(4-methanesulphonylamino-phenyl)-propionic acid 2- (3,5-dichloro-pyridin-4-yl)-1 -(3,4-dimethoxy-phenyl)ethyl ester (compound 17)
Compound 16 (26 mg, 0.05 mmoles) is dissolved in dry CH2CI2 (10 ml_) under nitrogen atmosphere. The solution is cooled to 00C and triethylamine (0.009 mL, 0.066 mmoles) and methanesulphonyl chloride (0.0052 mL, 0.06 mmoles) are added. The mixture is then allowed to react at room temperature for 17 hours. The reaction mixture is then diluted with water (15 mL) and extracted with AcOEt (2 x 30 mL). The organic phase is dried over Na2SO4 and the solvent is evaporated. The crude is purified by preparative HPLC to yield 10 mg of the title compound as a mixture of diastereoisomers. Table 6
Figure imgf000048_0001
EXAMPLE 9
Preparation of 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2- (3,5-dichloro-1-oxy-pyridin-4-yl)-ethanol (compound 18)
Intermediate 2b (100 mg, 0.25 mmoles) is dissolved in CHCL3 (3 mL). m-Chloro perbenzoic acid (mCPBA, 80 mg, 0.46 mmoles) is added and the resulting solution is kept at 00C overnight.
The mixture is then diluted with CHCb (5 mL) and washed with 1 N NaOH (5 ml). The organic phase is dried over Na2SO4 and the solvent is evaporated.
The crude product is purified by crystallization with ethanol. The white solid is filtered and washed with petroleum ether to yield 70 mg of the title compound.
The following compounds were prepared following the same route using suitable reagents:
Table 7
Figure imgf000049_0001
EXAMPLE 10
Preparation of 4-(2-piperidin-1-yl-ethoxy)-benzoic acid 1-(3- cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin- 4-yl)ethyl ester hydrochloride (compound 25) (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride)
(EDCHCI) (55 mg, eq.) is added to a solution of compound 18 (60 mg, 0.14 mmol), 4-(2-piperidin-1-yl-ethoxy)-benzoic acid (81 mg, 0.28 eq.) and 4-dimethylaminopyridine (DMAP) (37 mg, 0.5 eq.) in dry DMF (4 ml_) at room temperature under nitrogen atmosphere. The mixture is stirred at room temperature overnight, then it is treated with a saturated solution of NH4CI (20 ml) and extracted with EtOAc (2x20 ml). The combined organic layers are dried over Na2SO4 and the solvent is evaporated. The crude is purified by preparative HPLC. The oily residue is dissolved in ethyl acetate (2 ml) and added with a slight excess of a 1 M solution of dry HCI in ethyl acetate. After evaporation of the solvent the residue is crystallized from methanol/diethyl ether to give 14 mg of the hydrochloride salt. Table 8
Figure imgf000050_0001
Legend * NMR s = singlet d = doublet t = triplet q = quartet dd = doublet of doublets m = multiplet br = broad ESI=electrospray
PHARMACOLOGICAL ACTIVITY OF THE COMPOUNDS OF THE INVENTION
EXAMPLE 11
In vitro determination of PDE4 inhibitory activity in the cell free assay The U937 human monocytic cell line was used as source of PDE4 enzyme. Cells were cultured, harvested and supernatant fraction prepared essentially as described in Torphy TJ et al J. Pharmacol. Exp. Ther. 1992; 263:1195-1205.
PDE4 activity was determined in cells supernatants by assaying cAMP disappearance from the incubation mixtures. 50 μl of cell supernatant were incubated at 300C for 30 minutes in a final volume of 200 μl in the presence of 1.6 μM cAMP with or without the test compound (50 μl).
The concentration of the test compounds ranged between 10"12 M and 10"6 M. Reactions were stopped by heat inactivation (2.5 minutes at 1000C) and residual cAMP was measured using an electro-chemiluminescence (ECL) -based immunoassay.
The results, expressed as mean ± 95% confidence limits of the molar concentration of the test compound producing 50% inhibition of cAMP disappearance (IC50) are reported in Table 9 of Example 12. Percentage of inhibition of PDE4 activity was calculated, assuming cAMP disappearance in the absence of inhibitors as 100% and cAMP disappearance in heat inactivated samples as 0%.
All the IC50 values of the tested compounds, representative of the invention, were less than 0.2 microM.
EXAMPLE 12
In vitro determination of PDE4 inhibitory activity in the peripheral blood mononuclear cells (PBMCs) assay The assay, which is based on the known inhibitory activity exerted by
PDE4 inhibitors on the lipopolyshaccarides (LPS)-induced tumour necrosis factor-alpha (TNF-α release in peripheral blood mononuclear cells (PBMCs), was performed according to a method previously described (Hatzelmann A et al J. Pharmacol. Exp. Ther. 2001 ; 297:267-279; Draheim R et al J. Pharmacol. Exp. Ther. 2004; 308:555-563.
Cryopreserved human PBMCs, (100 μl/well) were incubated in 96-well plates (105 cells/well), for 30 min, in the presence or absence (50 microl) of the test compounds whose concentrations ranged from 10 12 M to 106 M. Subsequently, LPS (3 ng/ml) was added. After 18 h incubation at 37°C in a humidified incubator under an atmosphere of 95% air and 5% CO2, culture medium was collected and TNF-α measured by ELISA.
The results, expressed as mean ± 95% confidence limits of the molar concentration of the test compound producing 50% inhibition of LPS-induced TNF-a release (IC50) are reported in Table 9.
The effects of the tested compounds were calculated as percentage of inhibition of TNF-α release, assuming LPS-induced TNF-α production in the absence of inhibitor compound as 100% and basal TNF-α production of PBMCs in the absence of LPS as 0%. Table 9 - In vitro PDE4 inhibition activity of representative compounds of the invention
Figure imgf000053_0001
[EXAMPLE 13
Evaluation of the ability to inhibit the low affinity LPDE4 versus the ability to compete for the high affinity HPDE4
The affinity toward LPDE4 and HPDE4 was assessed as previously described respectively in Cortijo J et al Br J Pharmacol 1993, 108: 562-568 and Duplantier AJ et al J Med Chem 1996; 39: 120-125.
The concentration of the test compound ranged between 10-12 M and 10-5 M.
The results in terms of IC50 are reported in Table 10. In the case of LPDE4, the IC50 is the molar concentration of the test compound producing 50% inhibition of cAMP disappearance, while in the case of HPDE4, the IC50 is the molar concentration of the test compound producing 50% inhibition of the binding of [H3] rolipram.
The results indicate that the compounds of the invention inhibited LPDE4 with subnanomolar affinity and are considerably more selective toward LPDE4 versus HPDE4.
Table 10 - Activity profile of representative compounds of the invention
Figure imgf000054_0001

Claims

1. A compound of general formula (I)
Figure imgf000055_0001
(I) wherein: Z is selected from the group consisting of
(CH2)m wherein m = 0, 1 or 2; (CHb)nO wherein n=1, 2 or 3;
O(CH2)p wherein p=0, 1 , 2 or 3; CH2SO2; CHNR6; CH2NR6; NR6 wherein R6 is H or a linear or branched (C1-C4) alkyl;
OCOR4R5; and CR4R5 wherein
R4 is independently selected from H or a linear or branched (C1-C4) alkyl, preferably methyl, optionally substituted by a (C1-C4) cycloalkyl and
R5 is independently selected from the group consisting of
- linear or branched (C1-C4) alkyl, preferably methyl;
- phenyl;
- benzyl; - NH2; and - HNCOOR', wherein R' is linear or branched (C1-C4) alkyl, preferably t-butyl.
Ri and R2 are different or the same and are independently selected from the group consisting of - H;
- linear or branched (C-i-Cε) alkyl, optionally substituted by one or more substituents selected from (C3-C7) cycloalkyl or (C5-C7) cycloalkenyl;
- (C3-C7) cycloalkyl;
- (C5-C7) cycloalkenyl; - linear or branched (C2-C6) alkenyl; and
- linear or branched (C2-C6) alkynyl.
R3 is one or more substituents independently selected from the group consisting of H, CN, NO2, CFβ and halogen atoms.
A is a ring system, that is a mono- or bicyclic ring which may be saturated, partially unsaturated or unsaturated, such as aryl, (C3-C8) cycloalkyl or heteroaryl, said ring system A having 5 to 10 ring atoms in which at least one ring atom is a heteroatom (e.g. N, S or O), in which the optional substituent Rx on the A ring system may be one or more, may be the same or different, and is independently selected from the group consisting of: - linear or branched (Ci-Cβ) alkyl optionally substituted by one or more
(C3-C7) cycloalkyl;
- linear or branched (C2-C-6) alkenyl optionally substituted by one or more (C3-C7) cycloalkyl;
- linear or branched (C2-C6) alkynyl optionally substituted by one or more (C3-C7) cycloalkyl;
- (C5-C7) cycloalkenyl;
- phenyl;
- (C3-C7) heterocycloalkyl; - OR7 wherein R7 is selected from the group consisting of
- H;
- (C1-C10) alkyl optionally substituted by one or more (C3-C7) cycloalkyl; - (C3-C7) cycloalkyl;
- (C1-C4) alkyl-(C3-C7) heterocycloalkyl;
- CO (Ci-C6) alkyl;
- COO (C1-C6) alkyl;
- phenyl; - benzyl;
- (C1-C10) alkyl-NRβRθ wherein Re and R9 are independently selected from the group consisting of H, linear or branched (Ci-C6) alkyl and they form with the nitrogen atom to which they are linked a saturated, partially saturated or unsaturated ring, preferably NRSRΘ is linked to (C1-C10) alkyl forming for example saturated, partially saturated or unsaturated piperidine, oxazine, imidazole rings, wherein these rings are optionally substituted by (Ci-C4) alkyl; and
- halogen atoms; - CN;
- NO2;
- NR10R11 wherein R10 and Rn are different or the same and are independently selected from the group consisting of
- H; - linear or branched (Ci-C6) alkyl, optionally substituted with phenyl or (C3-C7) cycloalkyl;
- COC6H5;
- CO-(Ci-C4) alkyl; - COO-(Ci-C4) alkyl;
- CONH-(Ci-C6) alkyl-Ri2, wherein R12 is selected from the group consisting of
- H; - (C1-C4) alkyl;
Figure imgf000058_0001
- CONH (C1-C4) alkyl-N(Ci-C4) alkyl; or they form with the nitrogen atom to which they are linked a saturated or partially saturated ring, preferably a piperidyl ring; - (Ci-C4) alkyl-NRioRn;
- COR12 wherein R12 is phenyl or linear or branched (Ci-Cβ) alkyl;
- oxo;
- HNSO2R13 wherein R13 is (C1-C4) alkyl or a phenyl optionally substituted with halogen atoms or with a (C1-C4) alkyl group; - SO2R14 wherein R14 is (C1-C4) alkyl, OH or NR10R11 wherein R10 and Rn are as defined above;
- SOR15 wherein R15 is phenyl or (C1-C4) alkyl;
- SR16 wherein R16 is H, phenyl or (C1-C4) alkyl;
- COOR17 wherein R17 is H, (C1-C4) alkyl, phenyl or benzyl; and - (CH2)qORi8, wherein q=1 , 2, 3 or 4 and R18 is H or (C1-C4) cycloalkyl. and pharmaceutically acceptable salts and N-oxides on the pyridine ring thereof.
2. The compound of claim 1 wherein A is a phenyl optionally substituted with one or more Rx groups.
3. The compound of claim 1 wherein A is a heteroaryl ring optionally substituted with one or more Rx groups.
4. The compound of claim 3 wherein A is a heteroaryl ring selected from the group consisting of pyrrole, pyrazole, furan, thiophene, imidazole, oxazole, isoxazole, thiazole, pyridine, pyrimidine, pyrazine, pyridazine, and pyran.
5. The compound of any one of claims 1 to 4 wherein R3 is a halogen atom.
6. The compound of claim 5 wherein R3 is chlorine.
7. The compound of claim 6 having the general formula (II)
Figure imgf000059_0001
(II) 8. The compound of claim 7 wherein Z is (CH2)m with m equal to 0.
9. The compound of claim 8, which is 3-cyclopropylmethoxy-4- difluoromethoxy-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy- phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)ethyl ester (compound 14).
10. The compound of claim 8, which is 3-cyclopropylmethoxy-4- difluoromethoxy-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy- phenyl)-2-(3,5-dichloro-pyridin-4-yl)ethyl ester (compound 11).
11. The compound of claim 7 wherein Z is CHR5 where R5 is a linear or branched C1-C4 alkyl, preferably methyl.
12. The compound of claim 7 wherein Z is CR4R5 where R4 and R5 are both linear or branched C1-C4 alkyl and they form a ring with the carbon atom to which they are linked having 3, 4, 5 or 6 carbon atoms, preferably having 3 carbon atoms.
13. A process for the preparation of a compound of any of the preceding claims comprising the step of adding an acid of formula AZCOOH or an acyl chloride of formula AZCOCI or an isocyanate of formula AZNCO wherein A and Z are as defined above, to a solution of an alcohol derivative of general formula (2)
Figure imgf000060_0001
wherein Ri, R2 and R3 are as defined above.
14. A pharmaceutical composition comprising a compound of any of the claims 1 to 12 as active ingredient in admixture with one or more pharmaceutically acceptable carriers and/or excipients.
15. The pharmaceutical composition of claim 20 suitable for administration by inhalation.
16. The pharmaceutical composition of claim 14 or 15 wherein said composition further comprises an additional active ingredient selected from the classes of beta2-agonists, corticosteroids and anticholinergic or antimuscarinic agents.
17. The use of a compound of any of the claims 1 to 12 as a medicament.
18. The use of a compound of any of the claims 1 to 12 for the manufacture of a medicament.
19. The use of a compound of any of the claims 1 to 12 for the manufacture of a medicament for the prevention and/or treatment of any disease characterized by phosphodiesterase 4 (PDE4) overactivity and/or wherein an inhibition of PDE4 activity is desirable.
20. The use as in claim 19 wherein the disease is a disease of the respiratory tract characterized by airway obstruction.
21. The use as in claim 20 wherein the disease is selected from the group consisting of asthma or chronic bronchitis or chronic obstructive pulmonary disease.
22. A method of treating an inflammatory disease, disorder or condition characterized by or associated with an undesirable inflammatory immune response or induced by or associated with an excessive secretion of TNF-α and PDE4 which comprises administering to a subject in need thereof a therapeutically effective amount of a compound according to any of the claims 1 to 12.
PCT/EP2008/005843 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors WO2009018909A2 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
AU2008286027A AU2008286027B2 (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
ES08784827.1T ES2563478T3 (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl-alkyl alcohols as phosphodiesterase inhibitors
RS20160145A RS54606B1 (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
DK08784827.1T DK2185515T3 (en) 2007-08-08 2008-07-17 DERIVATIVES OF 1-PHENYL-2-PYRIDINYLALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS
MX2010001544A MX2010001544A (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors.
BRPI0814065A BRPI0814065B8 (en) 2007-08-08 2008-07-17 derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CA2695580A CA2695580C (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MEP-2010-19A ME00974B (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
JP2010519351A JP2010535722A (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinylalkyl alcohol as phosphodiesterase inhibitors
EA201000149A EA017530B1 (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
PL08784827T PL2185515T3 (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN2008801023963A CN101796028B (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
NZ583103A NZ583103A (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
KR1020107002838A KR101200683B1 (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyr1dinyl alkyl alcohols as phosphodiesterase inhibitors
EP08784827.1A EP2185515B1 (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
SI200831590T SI2185515T1 (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
TNP2010000044A TN2010000044A1 (en) 2007-08-08 2010-01-25 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
IL203712A IL203712A (en) 2007-08-08 2010-02-04 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
ZA2010/00832A ZA201000832B (en) 2007-08-08 2010-02-04 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
HK10112226.9A HK1145686A1 (en) 2007-08-08 2010-12-30
IL239466A IL239466A0 (en) 2007-08-08 2015-06-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
HRP20160292TT HRP20160292T1 (en) 2007-08-08 2016-03-22 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114019A EP2022783A1 (en) 2007-08-08 2007-08-08 "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP07114019.8 2007-08-08

Publications (2)

Publication Number Publication Date
WO2009018909A2 true WO2009018909A2 (en) 2009-02-12
WO2009018909A3 WO2009018909A3 (en) 2009-05-14

Family

ID=38754730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/005843 WO2009018909A2 (en) 2007-08-08 2008-07-17 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Country Status (38)

Country Link
US (7) US7923565B2 (en)
EP (3) EP2022783A1 (en)
JP (3) JP2010535722A (en)
KR (1) KR101200683B1 (en)
CN (1) CN101796028B (en)
AR (1) AR068057A1 (en)
AU (1) AU2008286027B2 (en)
BR (1) BRPI0814065B8 (en)
CA (1) CA2695580C (en)
CL (1) CL2008002330A1 (en)
CO (1) CO6290760A2 (en)
CY (2) CY1117324T1 (en)
DK (2) DK2947068T3 (en)
EA (1) EA017530B1 (en)
ES (2) ES2655816T3 (en)
GE (1) GEP20125537B (en)
HK (1) HK1145686A1 (en)
HR (2) HRP20160292T1 (en)
HU (2) HUE035557T2 (en)
IL (2) IL203712A (en)
JO (1) JO3181B1 (en)
LT (1) LT2947068T (en)
MA (1) MA31586B1 (en)
ME (1) ME00974B (en)
MX (1) MX2010001544A (en)
MY (1) MY152692A (en)
NO (1) NO2947068T3 (en)
NZ (1) NZ583103A (en)
PE (1) PE20090698A1 (en)
PL (2) PL2185515T3 (en)
PT (2) PT2947068T (en)
RS (2) RS54606B1 (en)
SI (2) SI2185515T1 (en)
TN (1) TN2010000044A1 (en)
TW (1) TWI444366B (en)
UA (1) UA99622C2 (en)
WO (1) WO2009018909A2 (en)
ZA (1) ZA201000832B (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
WO2011131663A1 (en) 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. "process for providing particles with reduced electrostatic charges"
WO2012016889A2 (en) 2010-08-03 2012-02-09 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
WO2012016845A2 (en) 2010-08-03 2012-02-09 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
US20120082727A1 (en) * 2010-09-30 2012-04-05 Chiesi Farmaceutici S.P.A. Use of magnesium stearate in dry powder formulations for inhalation
WO2012168226A1 (en) 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2013045280A1 (en) 2011-09-26 2013-04-04 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2013057013A2 (en) 2011-10-21 2013-04-25 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2013182451A1 (en) 2012-06-04 2013-12-12 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US20140155391A1 (en) * 2012-12-05 2014-06-05 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
WO2014086849A1 (en) 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. Phenylethylpyridine derivatives as pde4-inhibitors
WO2015052169A1 (en) 2013-10-10 2015-04-16 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
WO2015059050A1 (en) 2013-10-22 2015-04-30 Chiesi Farmaceutici S.P.A. Process for the preparation of a pde4 inhibitor
WO2015082616A1 (en) 2013-12-05 2015-06-11 Chiesi Farmaceutici S.P.A. Heteroaryl derivatives for the treatment of respiratory diseases
WO2015082619A1 (en) 2013-12-05 2015-06-11 Chiesi Farmaceutici S.P.A. Benzhydryl derivatives for the treatment of respiratory diseases
WO2015185649A1 (en) * 2014-06-05 2015-12-10 Chiesi Farmaceutici S.P.A. Aminoester derivatives
WO2019129586A1 (en) 2017-12-28 2019-07-04 Chiesi Farmaceutici S.P.A. Use of 1-phenyl-2-pyridinyl alkyl alcohol derivatives for treating cystic fibrosis
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023208982A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Crystal form of a pde4 inhibitor
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
WO2024062006A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062005A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2928880B1 (en) * 2012-12-05 2018-02-14 Chiesi Farmaceutici S.p.A. Phenylethylpyridine derivatives as pde4-inhibitors and muscarinic receptor antagonists
KR20150091061A (en) 2012-12-05 2015-08-07 키에시 파르마슈티시 엣스. 피. 에이. Phenylethylpyridine derivatives as pde4-inhibitors
EP3152202B1 (en) * 2014-06-04 2018-11-28 Chiesi Farmaceutici S.p.A. 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors and muscarinic m3 receptor antagonists
EP3152203A1 (en) 2014-06-04 2017-04-12 Chiesi Farmaceutici S.p.A. 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)- 2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors
US9326976B2 (en) 2014-06-05 2016-05-03 Chiesi Farmaceutici S.P.A. Carbamate derivatives
TW201710254A (en) * 2015-06-01 2017-03-16 吉斯藥品公司 Aminoester derivatives
WO2020217510A1 (en) 2019-04-26 2020-10-29 株式会社Ｆｕｊｉ Printing parameter acquisition device and printing parameter acquisition method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002465A1 (en) 1992-07-28 1994-02-03 Rhone-Poulenc Rorer Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF
EP1634606A1 (en) 2003-03-31 2006-03-15 Kyowa Hakko Kogyo Co., Ltd. Drug for airway administration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
WO1998012178A1 (en) 1996-09-17 1998-03-26 Merck & Co., Inc. Method of preparing phosphodiesterase iv inhibitors
CA2364653A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
ES2436606T3 (en) 2003-03-12 2014-01-03 Celgene Corporation 7-amido-isoindolyl compounds and their pharmaceutical uses
US7888381B2 (en) * 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
WO2008006509A1 (en) * 2006-07-14 2008-01-17 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2110375A1 (en) 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
MX346424B (en) 2010-08-03 2017-03-21 Chiesi Farm Spa Dry powder formulation comprising a phosphodiesterase inhibitor.
CN106377503A (en) 2010-08-03 2017-02-08 奇斯药制品公司 Pharmaceutical formulations comprising phosphodiesterase inhibitor
AU2012266514A1 (en) 2011-06-06 2014-01-09 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2760838B1 (en) 2011-09-26 2017-05-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
RU2617401C2 (en) 2011-10-21 2017-04-25 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as inhibitors
RU2637945C2 (en) 2012-06-04 2017-12-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Derivatives of 1-phenyl-2-pyridinyl-alkyl alcohols as phosphodiesterase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002465A1 (en) 1992-07-28 1994-02-03 Rhone-Poulenc Rorer Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF
EP1634606A1 (en) 2003-03-31 2006-03-15 Kyowa Hakko Kogyo Co., Ltd. Drug for airway administration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JACOBITZ, S ET AL., MOL. PHARMACOL, vol. 50, 1996, pages 891 - 899

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056176B2 (en) 2009-02-06 2015-06-16 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
WO2010089107A1 (en) 2009-02-06 2010-08-12 Chiesi Farmaceutici S.P.A. Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors
CN102317262A (en) * 2009-02-06 2012-01-11 奇斯药制品公司 Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
AU2010211274B2 (en) * 2009-02-06 2016-03-17 Chiesi Farmaceutici S.P.A. Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors
US8859778B2 (en) 2009-02-06 2014-10-14 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
CN102317262B (en) * 2009-02-06 2014-08-06 奇斯药制品公司 Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
US8648204B2 (en) 2009-02-06 2014-02-11 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
EA019113B1 (en) * 2009-02-06 2014-01-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase 4 (pde4) inhibitors
US8440834B2 (en) 2009-02-06 2013-05-14 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
WO2011131663A1 (en) 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. "process for providing particles with reduced electrostatic charges"
EA027692B1 (en) * 2010-08-03 2017-08-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Dry powder formulation comprising a phosphodiesterase inhibitor
WO2012016845A3 (en) * 2010-08-03 2012-04-12 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
CN103052378A (en) * 2010-08-03 2013-04-17 奇斯药制品公司 Pharmaceutical formulation comprising phosphodiesterase inhibitor
EP3246016A1 (en) 2010-08-03 2017-11-22 Chiesi Farmaceutici S.p.a. Dry powder formulation comprising a phosphodiesterase inhibitor
KR101803121B1 (en) * 2010-08-03 2017-11-29 키에시 파르마슈티시 엣스. 피. 에이. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
CN106890165A (en) * 2010-08-03 2017-06-27 奇斯药制品公司 Dry powder formulations comprising CD-840
JP2013532705A (en) * 2010-08-03 2013-08-19 チェシ ファーマスーティシ エス．ピー．エイ． Dry powder formulation containing a phosphodiesterase inhibitor
EP3143987A1 (en) 2010-08-03 2017-03-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
WO2012016889A3 (en) * 2010-08-03 2012-04-19 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
CN103052379A (en) * 2010-08-03 2013-04-17 奇斯药制品公司 Dry powder formulation comprising a phosphodiesterase inhibitor
US9132121B2 (en) 2010-08-03 2015-09-15 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
CN106377503A (en) * 2010-08-03 2017-02-08 奇斯药制品公司 Pharmaceutical formulations comprising phosphodiesterase inhibitor
EA024922B1 (en) * 2010-08-03 2016-11-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Dry powder formulation comprising a phosphodiesterase inhibitor
AU2011287711B2 (en) * 2010-08-03 2016-10-27 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
WO2012016889A2 (en) 2010-08-03 2012-02-09 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
WO2012016845A2 (en) 2010-08-03 2012-02-09 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
US9358224B2 (en) 2010-08-03 2016-06-07 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
US9308200B2 (en) 2010-08-03 2016-04-12 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
US20120082727A1 (en) * 2010-09-30 2012-04-05 Chiesi Farmaceutici S.P.A. Use of magnesium stearate in dry powder formulations for inhalation
WO2012041717A1 (en) 2010-09-30 2012-04-05 Chiesi Farmaceutici S.P.A. Use of magnesium stearate in dry powder formulations for inhalation
CN103562185A (en) * 2011-06-06 2014-02-05 奇斯药制品公司 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN106946848A (en) * 2011-06-06 2017-07-14 奇斯药制品公司 It is used as the derivative of the pyridyl alkyl alcohol of 1 phenyl 2 of phosphodiesterase inhibitors
WO2012168226A1 (en) 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN106946848B (en) * 2011-06-06 2022-01-04 奇斯药制品公司 Derivatives of 1-phenyl-2-pyridylalkylalcohols as phosphodiesterase inhibitors
US9931327B2 (en) 2011-06-06 2018-04-03 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US9265768B2 (en) 2011-09-26 2016-02-23 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2013045280A1 (en) 2011-09-26 2013-04-04 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US9024027B2 (en) 2011-10-21 2015-05-05 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2013057013A2 (en) 2011-10-21 2013-04-25 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2013057013A3 (en) * 2011-10-21 2013-06-20 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
RU2637945C2 (en) * 2012-06-04 2017-12-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Derivatives of 1-phenyl-2-pyridinyl-alkyl alcohols as phosphodiesterase inhibitors
WO2013182451A1 (en) 2012-06-04 2013-12-12 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US9944612B2 (en) * 2012-12-05 2018-04-17 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
US20140155391A1 (en) * 2012-12-05 2014-06-05 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
WO2014086849A1 (en) 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. Phenylethylpyridine derivatives as pde4-inhibitors
WO2014086865A1 (en) 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
TWI628166B (en) * 2012-12-05 2018-07-01 吉斯藥品公司 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
KR102192739B1 (en) * 2012-12-05 2020-12-18 키에시 파르마슈티시 엣스. 피. 에이. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
RU2655170C2 (en) * 2012-12-05 2018-05-24 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
KR20150092214A (en) * 2012-12-05 2015-08-12 키에시 파르마슈티시 엣스. 피. 에이. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
WO2015052169A1 (en) 2013-10-10 2015-04-16 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
US10759761B2 (en) * 2013-10-22 2020-09-01 Chiesi Farmaceutici S.P.A. Process for the preparation of a PDE4 inhibitor
EP3587400A2 (en) 2013-10-22 2020-01-01 Chiesi Farmaceutici S.p.A. Process for the preparation of a pde4 inhibitor
US11981639B2 (en) 2013-10-22 2024-05-14 Chiesi Farmaceutici S.P.A. Process for the preparation of a PDE4 inhibitor
EP4059921A1 (en) 2013-10-22 2022-09-21 Chiesi Farmaceutici S.p.A. Process for the preparation of a pde4 inhibitor
WO2015059050A1 (en) 2013-10-22 2015-04-30 Chiesi Farmaceutici S.P.A. Process for the preparation of a pde4 inhibitor
US11352327B2 (en) 2013-10-22 2022-06-07 Chiesi Farmaceutici S.P.A. Process for the preparation of a PDE4 inhibitor
EP3798209A1 (en) 2013-10-22 2021-03-31 Chiesi Farmaceutici S.p.A. Process for the preparation of a crystal form of a pde4 inhibitor
EP3293176A1 (en) 2013-10-22 2018-03-14 Chiesi Farmaceutici S.p.a. Crystal form of a pde4 inhibitor
RU2682660C2 (en) * 2013-10-22 2019-03-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Method of obtaining pde4 inhibitor
RU2682660C9 (en) * 2013-10-22 2019-06-21 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Method of obtaining pde4 inhibitor
WO2015082619A1 (en) 2013-12-05 2015-06-11 Chiesi Farmaceutici S.P.A. Benzhydryl derivatives for the treatment of respiratory diseases
WO2015082616A1 (en) 2013-12-05 2015-06-11 Chiesi Farmaceutici S.P.A. Heteroaryl derivatives for the treatment of respiratory diseases
KR20170015294A (en) * 2014-06-05 2017-02-08 키에시 파르마슈티시 엣스. 피. 에이. Aminoester derivatives
US9763924B2 (en) 2014-06-05 2017-09-19 Chiesi Farmaceutici S.P.A. Aminoester derivatives
WO2015185649A1 (en) * 2014-06-05 2015-12-10 Chiesi Farmaceutici S.P.A. Aminoester derivatives
US10117860B2 (en) 2014-06-05 2018-11-06 Chiesi Farmaceutici S.P.A. Aminoester derivatives
US20150352091A1 (en) * 2014-06-05 2015-12-10 Chiesi Farmaceutici S.P.A. Aminoester derivatives
AU2015270539B2 (en) * 2014-06-05 2018-11-08 Chiesi Farmaceutici S.P.A. Aminoester derivatives
EA032761B1 (en) * 2014-06-05 2019-07-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Aminoester derivatives
KR102420323B1 (en) 2014-06-05 2022-07-13 키에시 파르마슈티시 엣스. 피. 에이. Aminoester derivatives
WO2019129586A1 (en) 2017-12-28 2019-07-04 Chiesi Farmaceutici S.P.A. Use of 1-phenyl-2-pyridinyl alkyl alcohol derivatives for treating cystic fibrosis
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023208982A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Crystal form of a pde4 inhibitor
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
WO2024062006A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062005A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Also Published As

Publication number Publication date
NO2947068T3 (en) 2018-04-07
US20090048220A1 (en) 2009-02-19
MY152692A (en) 2014-11-28
DK2947068T3 (en) 2018-01-15
JP6023846B2 (en) 2016-11-09
ME00974B (en) 2012-06-20
PL2947068T3 (en) 2018-04-30
US20110144070A1 (en) 2011-06-16
US20140135301A1 (en) 2014-05-15
BRPI0814065A2 (en) 2015-01-06
EA017530B1 (en) 2013-01-30
HRP20160292T1 (en) 2016-04-22
HRP20180212T1 (en) 2018-03-09
BRPI0814065B1 (en) 2020-02-11
DK2185515T3 (en) 2016-02-29
HUE027171T2 (en) 2016-10-28
HUE035557T2 (en) 2018-05-02
JP2015163629A (en) 2015-09-10
EP2185515B1 (en) 2016-01-06
EP2022783A1 (en) 2009-02-11
CY1117324T1 (en) 2017-04-26
US9000177B2 (en) 2015-04-07
KR101200683B1 (en) 2012-11-13
TWI444366B (en) 2014-07-11
CL2008002330A1 (en) 2009-03-20
AU2008286027A1 (en) 2009-02-12
US8383826B2 (en) 2013-02-26
AR068057A1 (en) 2009-11-04
US7923565B2 (en) 2011-04-12
CY1119669T1 (en) 2018-04-04
AU2008286027B2 (en) 2013-02-21
RS56765B1 (en) 2018-04-30
JP2014037426A (en) 2014-02-27
JP2010535722A (en) 2010-11-25
WO2009018909A3 (en) 2009-05-14
US20120116091A1 (en) 2012-05-10
US20150018321A1 (en) 2015-01-15
PL2185515T3 (en) 2016-06-30
CA2695580C (en) 2016-10-04
US8203000B2 (en) 2012-06-19
MX2010001544A (en) 2010-03-15
US20130137648A1 (en) 2013-05-30
CN101796028B (en) 2013-07-10
AU2008286027A2 (en) 2010-04-01
ES2655816T3 (en) 2018-02-21
US9102619B2 (en) 2015-08-11
ZA201000832B (en) 2011-04-28
JP5746298B2 (en) 2015-07-08
IL203712A (en) 2016-08-31
MA31586B1 (en) 2010-08-02
PE20090698A1 (en) 2009-07-06
EA201000149A1 (en) 2010-08-30
EP2947068A1 (en) 2015-11-25
KR20100050501A (en) 2010-05-13
EP2185515A2 (en) 2010-05-19
TN2010000044A1 (en) 2011-09-26
JO3181B1 (en) 2018-03-08
PT2185515E (en) 2016-03-31
BRPI0814065B8 (en) 2021-05-25
EP2947068B1 (en) 2017-11-08
IL239466A0 (en) 2015-07-30
NZ583103A (en) 2012-03-30
SI2185515T1 (en) 2016-04-29
ES2563478T3 (en) 2016-03-15
LT2947068T (en) 2018-01-25
PT2947068T (en) 2018-01-12
US20110144075A1 (en) 2011-06-16
TW200916440A (en) 2009-04-16
GEP20125537B (en) 2012-05-25
CO6290760A2 (en) 2011-06-20
UA99622C2 (en) 2012-09-10
HK1145686A1 (en) 2011-04-29
CA2695580A1 (en) 2009-02-12
RS54606B1 (en) 2016-08-31
SI2947068T1 (en) 2018-02-28
CN101796028A (en) 2010-08-04

Similar Documents

Publication Publication Date Title
CA2695580C (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2225205B1 (en) Ester derivatives as phosphodiesterase inhibitors
EP2044023A1 (en) Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
JP2006528659A (en) Nicotinamide derivatives useful as PDE4 inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880102396.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08784827

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 10006261

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2010020179

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 11677

Country of ref document: GE

Ref document number: 2695580

Country of ref document: CA

Ref document number: 2010519351

Country of ref document: JP

Ref document number: 583103

Country of ref document: NZ

Ref document number: 2008286027

Country of ref document: AU

Ref document number: 203712

Country of ref document: IL

Ref document number: 450/KOLNP/2010

Country of ref document: IN

Ref document number: 201000149

Country of ref document: EA

Ref document number: 12010500280

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 20107002838

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/001544

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: DZP2010000109

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2008286027

Country of ref document: AU

Date of ref document: 20080717

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008784827

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PI 2010000536

Country of ref document: MY

Ref document number: A201001159

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0814065

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100204

WWE Wipo information: entry into national phase

Ref document number: 239466

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: P-2016/0145

Country of ref document: RS